Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00179738
Status:
TERMINATED
Last Update Posted:
2005-11-23
First Post:
2005-09-10
Brief Title:
A Multicenter Single-Arm Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide Revlimid CC-5013 in Subjects With Androgen Independent Prostate Cancer
Sponsor:
Celgene Corporation
Organization:
Celgene
Study Overview
Official Title:
A Multicenter Single-Arm Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide Revlimid In Subjects With Androgen Independent Prostate Cancer
Status:
TERMINATED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Subjects who qualify will receive single agent oral lenalidomide daily on days 1-21 every 28 day cycle Subjects will continue on study until documented disease progression
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None